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Abstract
Successful management of orthopaedic device-related infections requires combined surgical and antimicrobial therapy. Because of the
heterogeneity of clinical situations, controlled trials are lacking. Although rational concepts for surgical treatment have been published,
many aspects of antimicrobial therapy are still not well documented. In this review, some of these knowledge gaps are discussed, and
rational arguments for initial parenteral treatment are presented. In addition, the interpretation of data regarding bone penetration is
discussed. Whereas rifampin is now a standard combination partner in the treatment of staphylococcal infections, its role against
other microorganisms is still unclear. Finally, in view of the increasing prevalence of methicillin-resistant staphylococci and their
decreasing susceptibility to vancomycin, data are provided on linezolid and daptomycin, which can potentially be used in bone and
joint infections.
Keywords: Bone penetration, daptomycin, linezolid, orthopaedic device-related infection, rifampin, rifamycin derivatives
Article published online: 30 August 2012
Clin Microbiol Infect 2012; 18: 1176–1184
Corresponding author: W. Zimmerli, Unit of Infectious Diseases,
Basel University Medical Clinic, Rheinstrasse 26, 4410 Liestal,
Switzerland
E-mail: werner.zimmerli@unibas.ch
Introduction
Orthopaedic implants are increasingly being used to relieve
pain, allow rapid fracture healing, and improve both mobil-
ity and independence of patients. Although the overall
percentage of complications after orthopaedic procedures is
low, the absolute number is increasing, owing to the grow-
ing number of patients with implants. The treatment of
orthopaedic device-related infection (ODRI) requires inte-
grated and coordinated collaboration between orthopaedic
surgeons and infectious diseases specialists. Rational
treatment concepts have been proposed from expert
groups [1–4]. In this review, we focus on antimicrobial
therapy. Because few solid data for antimicrobial concepts
have been published, this review is based on observational
studies, pharmacological and experimental studies, and opinion
statements.
Initial Antimicrobial Treatment
Rationale for initial intravenous therapy
After microbiological sampling, intravenous antibiotics are
administered for several reasons. At initial clinical presenta-
tion, a high bacterial load is commonly found at the infection
site. Hence, the risk for emergence of resistance is highest
during this period, especially with subinhibitory antimicrobial
concentrations. Enteral resorption may be compromised
during the early postoperative period, whereas, with intrave-
nous therapy, bioavailability is predictable. In addition, much
higher doses of many compounds (e.g. b-lactams) can be
administered intravenously than by the oral route. In our
view, the latter argument is important, because the concen-
tration–time course in the bone compartments is difficult to
determine, in particular in the early phase of infection [5].
Hence, high serum antibiotic concentrations are required to
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obtain antimicrobial levels above the expected bacterial MICs
in the tissue compartment.
Factors influencing choice of compound
The case history, clinical findings and local epidemiology (e.g.
methicillin-resistant staphylococci, in particular methicillin-
resistant Staphylococcus aureus) allow an educated guess
regarding the empirical choice of antimicrobial agent. Antimi-
crobial resistance may emerge during treatment against
staphylococci, mainly when quinolones, rifampin or fusidic
acid are used [6–8], or during treatment against Pseudomonas
aeruginosa when quinolone is administered [9]. Therefore,
these agents cannot be recommended during the initial treat-
ment phase. In contrast, the emergence of b-lactam resis-
tance does not occur during anti-staphylococcal therapy. The
choice and doses of antimicrobial compound should be made
after considering: (i) potential causative microorganisms and
their corresponding range of MICs; (ii) pharmacodynamic
and pharmacokinetic properties; (iii) mechanism of action
(Table 1); (iv) tolerability; and (v) host toxicity [10–17].
Start and dosage of rifampin therapy
No study has investigated the optimal time for starting rifam-
pin therapy in patients with staphylococcal ODRI. Concerns
regarding liver toxicity or drug interactions with compounds
used for anaesthesia have been raised when rifampin is
administered preoperatively or immediately after surgery. In
one controlled study, it was started immediately after sur-
gery [6], and neither significant liver toxicity nor relevant
drug interactions were observed. From a pharmacological
point of view, this is plausible, because hepatitis is infre-
quently associated with rifampin, and enzyme induction may
become clinically relevant after several days [18]. However,
it is prudent not to use rifampin in the early course of infec-
tion, for the following reasons. First, perioperative rifampin
therapy increases the risk of superinfection with rifampin-
resistant staphylococci by selection pressure on the local
flora [19]. Second, emergence of resistance is highest when
the bacterial load is high [7]. Thus, there are arguments for
not starting rifampin combination therapy before all drains
are removed, the wound is dry, and the bacterial load is low-
ered by surgical treatment and initial antimicrobial therapy.
The optimal daily dosage and frequency of rifampin admin-
istration are unknown. Different regimens have been pub-
lished, although they have not been compared with each
other; they range from 300 mg twice daily [20] or 600 mg
once daily [21] to 450 mg twice daily [6] or 900 mg once
daily [22] (Table 2). The activity of rifampin is based on
Cmax/MIC. Hence, extrapolating these regimens will probably
reveal different Cmax/MIC values. Nevertheless, the clinical
outcome data do not suggest that one regimen is clearly less
effective than the other. In our experience, 900 mg once
daily is often not well tolerated. Thus, side effects and com-
pliance with co-administered drugs (e.g. quinolones twice
daily) should influence the choice of regimen on an individual
basis.
Switch from intravenous to oral drugs
Empirical therapy should be streamlined to directed intrave-
nous therapy as soon as the susceptibility pattern of the
microorganism(s) is known. Table 1 summarizes the most
common antimicrobial drugs used for initial empirical and
TABLE 1. Antimicrobial drugs used for initial intravenous empirical and directed therapy for orthopaedic device-related infec-
tion, and their serum concentrationsa
Compound Efficacy Doseb
Cmax
(mg/mL) T1/2 (h)
C1 h
(mg/mL)
C4 h
(mg/mL)
C6 h
(mg/mL)
C8 h
(mg/mL)
Recommended
daily dosec
Penicillin G T > MIC 5 Miod 130–235 0.5–0.67 50–80 2–3 1 £0.1 24/25 Mio in 5–6 doses
Amoxycillin T > MIC 2 g 110 1.0–1.5 50 3.5 1.2 £0.1 8 g in 4 doses
Clavulanate – 0.2 14 1.0–1.5 8 0.7 0.2 £0.1 0.8 g in 4 doses
Flucloxacillin T > MIC 1 g 130–210 1.0–1.5 30–55 2–8 0.5–2 £1 8 g in 4 doses
Cefazolin T > MIC 1 g 188 1.5–2.0 74 16.5 6 2 8 g in 4 doses
Cefuroxime T > MIC 1 g 100 1.0–2.0 24 4 1.1 £0.1 6 g in 4 doses
Cetriaxone T > MIC 1 g 200 8.0 190 75 55 – 2 g in 1 dose
Ceftazidime T > MIC 1 g 90 2.0–2.5 40 10 5 2 6 g in 3 doses
Cefepime T > MIC 2 g 163 2.0 86 19 – 4 6 g in 3 doses
Imipenem–cilastin T > MIC 0.5 g 45 1.0 21.5 2.6 0.6 – 2–4 g in 4 doses
Meropenem T > MIC 0.5 g 52 1.0 20 1–3 0.3–1.5 £1 6 g in 3 doses
Vancomycine AUC0–24/MIC 4.0–6.0 30 mg/kg in 2 doses
Cmax, maximum serum antibiotic concentration; C1 h to C8 h, serum antibiotic concentration after 1–8 h; T1/2, half-life in serum; T > MIC, time for which the antibiotic con-
centration exceeds the microbial MIC; AUC0–24/MIC, ratio of area under the concentration–time curve during a 24-h dosing period to MIC.
aData from [10–16].
bAfter intravenous administration of the indicated dose, the illustrated plasma concentrations (Cmax and C1 h to C8 h) were measured.
cIn the initial phase of treatment, the stated doses and intervals are based on the decrease in serum concentration (C1 h to C8 h) and the target to achieve high serum con-
centrations; they do not take into account the concentration–time course in the bone compartments. After measurement of MICs of the causative pathogen(s), the antibiotic
concentration should preferably remain at ‡50% of the dosing interval above the MIC (fT > MIC).
dMio = 1 · 106 units of penicillin, corresponding to 0.6 g.
eRecommended doses are based on AUC0–24/MIC and trough levels. For methicillin-resistant Staphylococcus aureus, an AUC0–24/MIC of >400 is recommended [17].
The recommendations are for adult patients with normal liver and renal function.
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directed intravenous therapy. Considering the rationale
mentioned above, intravenous treatment should be given for
7–14 days after initial surgery. Observation of the healing
process includes clinical and laboratory signs of inflammation,
formation of haematoma, wound healing, and wound secre-
tion. The decision to switch from an intravenous to an oral
formulation should be based on these parameters and
according to the disease course, after examination by an
interdisciplinary and experienced team, rather than on a
fixed time-point.
Bone Penetration of Antimicrobial Agents
Several reviews have been published on the bone/serum
ratio as a reflection of antibiotic concentration at the infec-
tion site [10,23–25]. The mean bone/serum concentrations
for most antibiotics range between 0.1 and 0.3 [10,25].
These data are helpful when considering variables such as
the MIC of the pathogen and the pharmacokinetic/pharma-
codynamic parameters of a drug. They should, however, be
interpreted with caution. Data are mainly obtained from
uninfected bone samples harvested during joint replace-
ment, and reflect bone/serum ratios after a single dose, not
in an equilibrium state. Considering the long-term treat-
ment commonly applied for ODRIs, it is important to note
that bone/serum ratios change over time unless equilibrium
between compartments has been reached (system hystere-
sis) [25]. Moreover, extracellular/serum and intracellular/
serum concentration ratios are often not distinguished [5].
Finally, the measurements can be made by using a variety
of methods, which may also involve technical drawbacks,
including the lack of validation guidance for stability, vari-
ability and linearity of the calibration curve, and the use of
appropriate internal calibration standards (reviewed in [25]).
In addition, methodological differences in sample prepara-
tion, homogenization of the bone and extraction of the
antimicrobial compound may reveal results that are difficult
to interpret for clinical practice. Moreover, bone/serum
ratio data frequently do not provide information on
whether or not the antibiotic is active [5]. The consider-
ations that should be taken into account when published
bone/serum concentration ratios are used are presented in
Table S1 [5,25] .
In the treatment of ODRI, differentiating between chronic
infection with an established biofilm and acute postoperative
or haematogenous infection is important. Bone sequesters
are often present in chronic but not in acute ODRI. Thus, in
chronic ODRI, antibiotic bone penetration and activity
against biofilm bacteria is important.
Despite these limitations of the available bone/serum con-
centration data, good bone penetration has been shown for
several oral antibiotics. For example, fluoroquinolones and
linezolid have bone/serum ratios ranging from 0.3 to 1.2 and
from 0.2 to 0.5, respectively [10,24,25]. Table 2 summarizes
the oral antimicrobial compounds that are commonly used in
osteomyelitis and have reasonable bone penetration. Most
data, however, arise from monotherapy [10,24–27], whereas
combination therapy is common for the treatment of ODRI
[28–32]. Thus, the respective role of each component in the
combination regimen against ODRI is clinically undefined,
except for quinolone–rifampin combinations [6].
Rifampin for Treatment of Pathogens other
than Staphylococci
The rationale and benefit of combination therapy with rifam-
pin for staphylococci has been shown in various studies
[6,33,34]. The role of rifampin in ODRIs caused by other
Gram-positive bacteria is still unclear.
Streptococcus species
The evidence on rifampin combination therapy is poor.
Rifampin is, however, commonly very active against most
streptococci, including nutritionally variant species [35–40].
Nevertheless, its effect on streptococcal biofilms is not pro-
ven [41]. Penicillin is still the treatment of choice against
streptococci. In vitro, the combination of penicillin and
TABLE 2. Oral antimicrobial compounds that are com-
monly used in osteomyelitis and have reasonable bone pene-
trationa
Class Compound
Recommended
dose for ODRI [1,4]
Fluoroquinolones Levofloxacin 750 mg once daily or
500 twice daily
Ciprofloxacin 750 mg twice daily
Moxifloxacin 400 mg once daily [26]
Lincosamide Clindamycinb 300–600 mg four times a day
Rifamycin Rifampin 300–450 mg twice daily [6,20]
or 600 mg once daily [21]
Tetracyclines Minocyclinec 100 mg twice daily
Doxycycline 100 mg twice daily
Oxazolidinones Linezolid 600 mg twice daily [28,32]
Miscellaneous Fusidic acid 500 mg three times a day
Trimethoprim–
sulphamethoxazole
1 DS three times a day
Metronidazoled 500 mg three times a day
to four times a day
DS, double strength; ODRI, orthopaedic device-related infection.
aData on bone penetration reviewed in [10,24,25].
bClindamycin is bacteriostatic. Most data on bone penetration are from the
1970s. Limitations of the data should be considered (Table S1).
cLack of data on bone penetration.
dData only for the intravenous route [27]. The bioavailabilities with the intrave-
nous route and the oral formulation are similar, indicating similar bone penetra-
tion.
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rifampin does not seem to be superior to penicillin alone.
With the checkerboard MIC technique, Maduri-Traczewski
et al. [42] detected synergism in 52% and no antagonism in
88 strains of group B streptococci. However, when minimal
bactericidal concentrations were considered, antagonism was
noted in 70% of the same strains. With respect to clinical
data, the use of rifampin combination therapy was reported
in a few case reports/series involving prosthetic valve endo-
carditis caused by nutritionally variant streptococci [43,44],
and periprosthetic joint infections (PJIs) caused by b-haemo-
lytic streptococci [45]. The effect of adding rifampin remains
unclear, however, when the outcome is not compared with
that of control patients. Taken together, these findings show
that, although rifampin is highly active against many strepto-
cocci in vitro, there is no evidence for its use, neither alone
nor in combination, in patients with ODRI.
Enterococcus species
Rifampin is active against enterococci in vitro, but it is only
bacteriostatic against most strains. However, resistance
emerges rapidly [46]. In animal and in vitro models, rifampin
combined with other agents (e.g. penicillin, ampicillin, vanco-
mycin, and gentamicin) did not provide a significant advan-
tage over the combination drug alone [46,47]. Ampicillin
and rifampin were even reported to be antagonistic [48].
The published experience with rifampin for the treatment
of enterococcal infection in humans is scarce [49]. Recently,
Holmberg et al. [50] evaluated the activity of ciprofloxacin,
ampicillin, vancomycin, and linezolid, alone and in combina-
tion with rifampin, against biofilms caused by Enterococcus
faecalis isolates obtained from PJIs. Similar to the results of
previous in vitro studies, the addition of rifampin to ampicil-
lin or vancomycin was not beneficial. However, the combi-
nation of linezolid and rifampin, and that of ciprofloxacin
and rifampin, was more efficient in reducing the biofilm than
each compound alone [50]. In addition, the emergence of
rifampin resistance was less frequent in combination therapy
than in monotherapy. Although this in vitro study gives a
new option for enterococcal treatment, clinical data are
lacking.
With the introduction of tigecycline, rifampin–tigecycline
combination therapy for ODRI has been considered. A
recent in vitro and animal study with clinical enterococcal iso-
lates from surgical wound infections showed synergism in
the combination as compared with tigecycline alone [51].
However, these results cannot be extrapolated to ODRI in
clinical practice. In summary, Enterococcus species remain dif-
ficult-to-treat pathogens that often persist or cause relapsing
infections [52]. Combination therapy with rifampin plus lin-
ezolid, daptomycin or tigecycline needs further investigation.
At this stage, the use of rifampin in enterococcal ODRI can-
not be recommended.
Propionibacterium species
These pathogens are generally susceptible to rifampin.
Although there are no EUCAST MIC breakpoints, it seems
reasonable to use a breakpoint of R > 0.5 mg/L [53]. Consid-
ering this value, the emergence of resistance seems possible
(patient 8 in [54]). Hence, and despite the results from an
animal study showing a considerable cure rate with rifampin
monotherapy [55], the compound should not be adminis-
tered alone. In an ODRI animal study, the combination of
daptomycin and rifampin achieved a cure rate of 63% [55].
Experimental or clinical data on penicillin–rifampin, or on
clindamycin–rifampin, are lacking. Although rifampin combina-
tions have been used with clindamycin, amoxycillin, and dap-
tomycin [56–61], the benefit of adding rifampin remains
unknown without a study comparing the combination with
monotherapy.
In the case of two-stage exchange of foreign material,
there is no rationale for the use of rifampin, as Propionibacte-
rium is highly susceptible to antibiotics, and commonly loses
its pathogenicity as soon as the device is removed. For other
surgical procedures (e.g. debridement and implant retention),
clinical data are lacking, although animal data are promising.
Gram-negative bacteria (GNB)
These bacteria are able to form biofilms, and they are playing
an increasing role in ODRI [62–65]. Rifampin is a hydropho-
bic compound that does not pass well through the mem-
branes of GNB. However, in combination with antibiotics
that permeabilize the bacterial membrane (e.g. colistin),
rifampin is effective against GNB [66–68]. Moreover, for
P. aeruginosa and Acinetobacter baumannii, in vitro and animal
studies have demonstrated synergistic activity when rifampin
and colistin are used (reviewed in [69,70]). Few studies have
investigated the susceptibility of biofilm-grown Burkholderia
cepacia and P. aeruginosa (isolates obtained from patients
with cystic fibrosis) to antibiotic combinations [71]. How-
ever, these data cannot be simply extrapolated to biofilm
bacteria that adhere to foreign bodies. In summary, the pub-
lished data on colistin–rifampin are not sufficient to recom-
mend this concept for ODRI.
Other Rifamycin Derivatives
Rifampin is a strong inducer of cytochrome P450 (CYP) iso-
enzyme CYP3A4 and, to a lesser extent, CYP2C8 and
CYP2C9, which increase the metabolism of many other co-
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administered drugs, thereby decreasing their serum concen-
trations [18]. To maintain the serum level of the co-adminis-
tered drug, its dose must be increased, and this may
compromise the patient’s compliance. As the presence of
comorbidities and therefore comedication is the rule in
patients with ODRI, rifamycin derivatives with less potential
for interaction are needed. The grading of CYP induction
caused by rifamycins is as follows: rifampin > rifapentine > ri-
fabutin > ABI-0043.
Rifapentine
This rifamycin derivative has an increased half-life as com-
pared with rifampin, and is active against Mycobacterium tuber-
culosis. Activity against staphylococci has also been shown
in vitro, revealing similar results to those for rifampin [72,73].
There are no data on the use of rifapentine in foreign-body
infections. Rifapentine is administered once weekly for
(latent) tuberculosis, making the compound attractive for
compliance, but difficult for management of drug interactions.
Therefore, without data from clinical studies, it is not a feasi-
ble alternative to rifampin for ODRI.
Rifabutin
Most data on drug interactions with rifabutin relate to anti-
retroviral medications in human immunodeficiency virus
patients treated for tuberculosis. Rifabutin has bactericidal
effects on staphylococci, and also acts intracellularly [74]. To
our knowledge, no published data exist on the use of rifabu-
tin combination therapy in ODRI. However, in selected
cases, namely solid organ transplant (e.g. treatment with ev-
erolimus) or human immunodeficiency virus patients (e.g.
treatment with protease inhibitors), the use of rifabutin (300
or 450 mg once daily) seems reasonable (unpublished obser-
vations). Importantly, the trough level of the co-administered
drug must be closely monitored, both during treatment and
after its cessation. Notably, protease inhibitors inhibit CYP
enzymes and cause an increase in serum rifabutin levels.
Hence, potential toxic side effects of rifabutin must also be
monitored.
ABI-0043
This rifamycin derivative has no CYP drug–drug interac-
tions, no strict cross-resistance with other rifamycins, and
very low MICs for staphylococci and streptococci [75].
Moreover, in an experimental model of foreign-body infec-
tion, it showed excellent activity against staphylococci. In
combination with levofloxacin, ABI-0043 cleared S. aureus
from the cage fluid and cured foreign-body infection in 92%
(22/24) of experiments [76]. However, clinical studies are
still lacking.
Antimicrobial Treatment for ODRI caused
by GNB
In ODRI caused by GNB, like that caused by staphylococci
[6], the duration of symptoms (i.e. acute) and the condition
of the soft tissue is crucial for the outcome if debridement
and implant retention are performed [62,64,65,77]. Resis-
tance to quinolones in GNB is associated with treatment fail-
ure, requiring implant removal [65]. However, in patients
fulfilling the criteria for debridement and implant retention,
intravenous therapy with cephalosporins or carbapenems
(Table 1), followed by oral quinolones, is recommended. In
contrast, both clinical observation and experimental results
from a foreign-body animal model showed treatment failure
with co-trimoxazole for ODRI [78]. However, co-trimoxa-
zole may be a valuable alternative for treating the adjacent
bone infection after device removal.
The most important factors in choosing an antimicrobial
compound for intravenous empirical and directed therapy
are the local epidemiology (e.g. prevalence of extended-spec-
trum b-lactamase producers), species identification and their
potential properties (e.g. AmpC producers), and the results
from correct antimicrobial susceptibility testing.
Linezolid and Daptomycin
The most frequent microorganisms causing PJIs are staphylo-
cocci [1]. The prevalence of methicillin-resistant staphylo-
cocci is increasing, and their susceptibility to vancomycin is
decreasing [79]. Therefore, the relevance of novel anti-staph-
ylococcal drugs, such as linezolid and daptomycin, for the
treatment of ODRI should be reviewed [80]. Notably, nei-
ther antibiotic is approved for bone and joint infections.
Linezolid
This compound is the first substance of a new class of anti-
microbial agents, the oxazolidinones. With current resistance
patterns, the steady-state peak plasma concentration of lin-
ezolid significantly surpasses the MIC90 of enterococci and
staphylococci [81]. It also has good penetration in human
bone [25]. Nevertheless, its use in bone and joint infections
is not promising [82]. In a rat model of S. aureus osteomyeli-
tis, the cure rate was disappointing [83]. When it is used in
combination with rifampicin, however, the eradication of bio-
film infections is better [84]; in a model of subcutaneous
implant-associated infection, 50% of methicillin-resistant
S. aureus infections could be cured with the combination
therapy [85]. Despite several observational studies in humans
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[28,86–89], linezolid efficacy in ODRI cannot be unambigu-
ously judged. The populations in these studies were hetero-
geneous, and no clear protocols for the definition of cure
were used. However, Soriano et al. [32] analysed 85 patients
with ODRI (24 acute and 61 chronic infections). In patients
with implant removal, the cure rates were similar with
linezolid alone and with linezolid combined with rifampin
(92% (22/24) vs. 100% (8/8)). In contrast, in patients with
implant retention, monotherapy had a lower cure rate than
combination therapy (47% (14/30) vs. 61% (14/23)). Notably,
the best cure rate with implant retention was observed in
patients with acute infections and combination therapy
(87.5% (7/8)). Although the latter constellation is a treatment
option, the side effects of linezolid must be considered.
Because bone and joint infections generally require pro-
longed treatment, the use of linezolid remains controversial.
Daptomycin
This compound is a cyclic lipopeptide antibiotic with concen-
tration-dependent bactericidal activity against Gram-positive
microorganisms [90]. The bactericidal effect occurs irrespec-
tive of inocula and bacterial growth phase [91–93]. Previous
clinical trials were interrupted because of muscle toxicity.
This was observed when daptomycin was administered twice
daily [94]. With once-daily application, this side effect did
not differ from comparators. Even at high doses (8 mg/kg),
and with prolonged treatment (up to 82 days), it was gener-
ally well tolerated, and rarely (<5%) caused musculoskeletal
symptoms [95].
In ODRI, daptomycin monotherapy appears not to be a
good option, because adherent staphylococci are phenotypi-
cally resistant to daptomycin. Indeed, monotherapy showed
a low cure rate in animal models of implant-associated infec-
tions [94,96]. In addition, in 12 patients with PJIs caused by
staphylococci, daptomycin (monotherapy, 4 mg/kg for a
minimum of 6 weeks) showed a low success rate [97].
However, at higher doses (6–10 mg/kg), daptomycin might
be a relevant combination partner for rifampin for the treat-
ment of ODRI. The combination was highly efficacious in
animal models of implant-associated infections [92,96,98].
Moreover, in these experiments, combination therapy could
completely prevent the emergence of rifampin resistance
[92]. Nevertheless, the efficacy of daptomycin for ODRI
cannot be conclusively judged, because there are few clinical
data. Analysis of the Cubist database is not helpful. Of 124
evaluable daptomycin-treated patients with osteomyelitis,
post-treatment results of patients with an ODRI were avail-
able for only 17 [99]. Notably, only three were treated with
retention. Nevertheless, these data allowed at least dose
finding, because patients with a dose of >4 mg/kg had a bet-
ter outcome than those with a lower dose (29% vs. 4% fail-
ure, p 0.013) [99].
In summary, the current clinical data do not allow the rec-
ommendation of daptomycin routinely for ODRI. However,
if daptomycin is considered for selected cases, the available
data point towards treatment: (i) with doses of 6–10 mg/kg
once daily; and (ii) in combination with rifampin. During pro-
longed treatment, creatine phosphokinase surveillance is
needed to rapidly detect muscle toxicity.
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